Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 114Thoracic 10Breast 8Sarcoma 5Genitourinary 5Gynecologic 4CNS 3Head & Neck 2Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Endocrine 1Dermatologic 1

Conditions

Melanoma 5Lymphoma, Large B-Cell, Diffuse 4Burkitt Lymphoma 4Sezary Syndrome 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasm Metastasis 3Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Lymphocytic, Chronic, B-Cell 3Intraocular Lymphoma 3Immunoblastic Lymphadenopathy 3Hodgkin Disease 3Ovarian Neoplasms 2Lymphoma 2Fallopian Tube Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Wilms Tumor 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Sarcoma 1Recurrence 1

Interventions

pembrolizumab 16Cyclophosphamide 8Nivolumab 7Gemcitabine 6Paclitaxel 5Drug Therapy 5Docetaxel 5fludarabine 4aldesleukin 4Oxaliplatin 4Fluorouracil 4Carboplatin 4ulixertinib 3spartalizumab 3Trastuzumab 3Radiotherapy 3Leucovorin 3Capecitabine 3trametinib 2tovorafenib 2pertuzumab 2pegilodecakin 2pazopanib 2palbociclib 2osimertinib 2enzalutamide 2cemiplimab 2atezolizumab 2Taxes 2Specimen Handling 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × Irinotecan × Dermatologic × Clear all
NCT06483555 2026-04-23

PANGEA

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Recruiting
104 enrolled
DermatologicGastrointestinal

Pancreatic Neoplasms, Neoplasms, Basal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡